文献速递贫血与红细胞疾病

羟基脲减轻镰状细胞贫血患者脑代谢应激

Hydroxyurea reduces cerebral metabolic stress in patients with sickle cell anemia.
PubMed 文献 · Blood · 2019-03-11

该前瞻性研究纳入84例镰状细胞贫血患者,按治疗分为未接受疾病修饰治疗组、羟基脲组和慢性输血治疗组,采用脑磁共振成像测量脑血流量和氧摄取分数。结果显示三组全脑脑血流量无差异,但全脑氧摄取分数存在显著差异,未治疗组最高、羟基脲组居中、慢性输血组最低;羟基脲组高缺血风险白质比例低于未治疗组但高于慢性输血组。作者认为羟基脲可能通过减轻脑代谢应激提供神经保护,但程度不及慢性输血治疗。

要点

  • 三组全脑脑血流量无显著差异(P = .148)。
  • 全脑氧摄取分数三组间显著不同(P < .001),未治疗组中位数42.9%最高,羟基脲组40.7%居中,慢性输血组35.3%最低。
  • 羟基脲组高缺血风险白质比例低于未治疗组(P = .025和P = .034),但高于慢性输血组(P = .018和P = .029)。

核心结论

  • 作者认为羟基脲可能通过减轻镰状细胞贫血患者的脑代谢应激提供神经保护,但程度不及慢性输血治疗。

研究设计与样本

  • 前瞻性研究,纳入84例镰状细胞贫血患者,按治疗分为未接受疾病修饰治疗组、羟基脲组和慢性输血治疗组,采用脑磁共振成像进行体素级脑血流量和氧摄取分数测量。

主要发现

  • 三组全脑脑血流量无显著差异(P = .148)。
  • 全脑氧摄取分数三组间显著不同(P < .001):未治疗组中位数42.9%(四分位距39.1%-49.1%),羟基脲组中位数40.7%(四分位距34.9%-43.6%),慢性输血组中位数35.3%(四分位距32.2%-38.9%)。
  • 以氧摄取分数大于40%和42.5%定义的高缺血风险白质比例,羟基脲组低于未治疗组(分别为P = .025和P = .034),但高于慢性输血组(分别为P = .018和P = .029)。

关键数值与推荐

  • 高缺血风险白质定义为氧摄取分数大于40%和42.5%。
  • 全脑氧摄取分数中位数:未治疗组42.9%(四分位距39.1%-49.1%),羟基脲组40.7%(四分位距34.9%-43.6%),慢性输血组35.3%(四分位距32.2%-38.9%)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Chronic transfusion therapy (CTT) prevents stroke in selected patients with sickle cell anemia (SCA). We have shown that CTT mitigates signatures of cerebral metabolic stress, reflected by elevated oxygen extraction fraction (OEF), which likely drives stroke risk reduction. The region of highest OEF falls within the border zone, where cerebral blood flow (CBF) nadirs; OEF in this region was reduced after CTT. The neuroprotective efficacy of hydroxyurea (HU) remains unclear. To test our hypothesis that patients receiving HU therapy have lower cerebral metabolic stress compared with patients not receiving disease-modifying therapy, we prospectively obtained brain magnetic resonance imaging scans with voxel-wise measurements of CBF and OEF in 84 participants with SCA who were grouped by therapy: no disease-modifying therapy, HU, or CTT. There was no difference in whole-brain CBF among the 3 cohorts (P = .148). However, whole-brain OEF was significantly different (P < .001): participants without disease-modifying therapy had the highest OEF (median 42.9% [interquartile range (IQR) 39.1%-49.1%]), followed by HU treatment (median 40.7% [IQR 34.9%-43.6%]), whereas CTT treatment had the lowest values (median 35.3% [IQR 32.2%-38.9%]). Moreover, the percentage of white matter at highest risk for ischemia, defined by OEF greater than 40% and 42.5%, was lower in the HU cohort compared with the untreated cohort (P = .025 and P = .034 respectively), but higher compared with the CTT cohort (P = .018 and P = .029 respectively). We conclude that HU may offer neuroprotection by mitigating cerebral metabolic stress in patients with SCA, but not to the same degree as CTT.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Fields ME, Guilliams KP, Ragan D, et al. Hydroxyurea reduces cerebral metabolic stress in patients with sickle cell anemia. Blood. 2019. PMID: 30858231. doi:10.1182/blood-2018-09-876318

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。